Aevi Genomic Medicine, LLC

Clinical trials sponsored by Aevi Genomic Medicine, LLC, explained in plain language.

Now part of Avalo Therapeutics, Inc. AVTX NASDAQ

A subsidiary of Cerecor, focused on genomic medicine for rare diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

Personalized ADHD drug shows promise in early trial for teens

Disease control Completed

This early-stage study tested a drug called NFC-1 in 30 adolescents aged 12-17 with ADHD who also have specific genetic changes affecting brain receptors. The goal was to check the drug's safety and how the body processes it, while also looking for signs it might reduce ADHD symp…

Phase 1 • Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company • Aim: Disease control

Last updated Jun 27, 2026 07:55 UTC

Aevi Genomic Medicine, LLC

Personalized ADHD drug shows promise in early trial for teens